Improved patient-reported outcomes in patients with psoriatic arthritis treated with abatacept: results from a phase 3 trial

Improved patient-reported outcomes in patients with psoriatic arthritis treated with abatacept: results from a phase 3 trial

Abstract Background To explore the effect of abatacept treatment on patient-reported outcomes (PROs) in psoriatic arthritis (PsA). Methods Patients with PsA were randomised (1:1) to subcutaneous abatacept 125 mg weekly/placebo for 24 weeks with early escape (EE) to open-label abatacept (week 16). Ad...

Full description

Bibliographic Details
Main Authors: Vibeke Strand, Evo Alemao, Thomas Lehman, Alyssa Johnsen, Subhashis Banerjee, Harris A. Ahmad, Philip J. Mease
Format: Article
Language:English
Published: BMC 2018-12-01
Series:Arthritis Research & Therapy
Subjects:
DMARDs (biologic)
Outcomes research
Patient perspective
Psoriatic arthritis
Online Access:http://link.springer.com/article/10.1186/s13075-018-1769-7

Internet

http://link.springer.com/article/10.1186/s13075-018-1769-7

Similar Items